The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
-
Page/Page column 95
(2018/02/28)
Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin
A compound of formual (I) or pharmaceutically acceptable salts or derivatives thereof; wherein variables are as defined in the specification. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor α4β1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.
-
(2008/06/13)
Pyridone-based peptidomimetic inhibitors of interleukin-1β-converting enzyme (ICE)
New potent, reversible inhibitors of recombinant human Interleukin-1 β-converting enzyme (ICE, caspase-1) with significantly reduced peptide character are described. The compounds were designed by incorporation of pyridone and pyrimidone heterocyclic replacements for the P2-P3 amino acids of the native substrate and were optimised by manipulation of peripheral alkyl and aryl substituents.
Semple, Graeme,Ashworth, Doreen M.,Baker, Graham R.,Batt, Andrzej R.,Baxter, Andrew J.,Benzies, David W.M.,Elliot, Lucy H.,Evans, D. Michael,Franklin, Richard J.,Hudson, Peter,Jenkins, Paul D.,Pitt, Gary R.,Rooker, David P.,Sheppard, Andrew,Szelke, Michael,Yamamoto, Satoshi,Isomura, Yasuo
p. 1337 - 1342
(2007/10/03)
More Articles about upstream products of 183666-09-3